About US
Contact us
-
The Art and Science of Forecasting with Clinical InformaticsThe art and science of forecasting with clinical informatics The pharmaceutical industry continues to strive to improve the quality and efficiency of clinical trials but many challenges remain with2016/7/25
-
Sandoz Enbrel biosim cruises at FDA panel, endangering key Amgen salesIn the second straight resounding vote in favor of a biosimilar in as many days, Sandoz’s version of Amgen’s Enbrel earned unanimous support from an FDA panel Wednesday. With the 20-0 vote, Novartis’2016/7/25
-
Pfizer's superselling Prevnar 13 jab wins expanded use in U.S.Already the world’s best-selling vaccine, Pfizer’s ($PFE) Prevnar 13 got yet another boost Tuesday with an expanded FDA approval in adults aged 18 to 49. Prevnar, which reeled in $6.2 billion last ye2016/7/22
-
In unanimous vote, FDA committee backs Amgen's Humira biosimWith billions at stake, Amgen’s biosimilar of AbbVie megablockbuster Humira won the unanimous backing of an FDA panel Tuesday, putting the company just an FDA approval away from a potentially huge sal2016/7/22
-
The Art and Science of Forecasting with Clinical InformaticsThe art and science of forecasting with clinical informatics The pharmaceutical industry continues to strive to improve the quality and efficiency of clinical trials but many challenges remain with2016/7/21
-
FDA staffers like Sandoz' biosimilarity data for copy of Amgen's EnbrelAmgen ($AMGN) is spending Tuesday making its case for a biosimilar approval before an FDA advisory committee. But come Wednesday, it’ll be Novartis’ ($NVS) Sandoz doing the same with a copy of an Amge2016/7/21
-
Merck KGaA to build $115M Boston hub, aiming for a higher profile in biopharma hotspotBig Pharma is all about beefing up its presence in the Boston area--a hotspot for biotech. And Merck KGaA is the latest to undertake a construction project. Tuesday, the German drugmaker announced it2016/7/20
-
UPDATED: J&J hikes forecast as standouts Imbruvica, Xarelto crank up pharma growthOnce again, Johnson & Johnson’s pharma engine powered top-line growth, with top performers Imbruvica, Xarelto and Daklinza all racking up impressive gains. Thanks to that “notable strength,” the h2016/7/20
-
Patheon Has Made an Initial Public Offering of Ordinary SharesPatheon has made an initial public offering of 30,487,805 of its ordinary shares This figure is added from Patheon selling 25,609,756 ordinary shares and the selling stockholder selling 4,878,049 ord2016/7/19
-
Mesa Labs Acquires Assets of CoaChrom Diagnostica and bioTRADING BeneluxMesa Laboratories' subsidiary Mesa France is acquiring assets and liabilities of two European distributors. These acquisitions involved CoaChrom Diagnostica of Austria and bioTRADING Benelux of the N2016/7/19